RxDoctor Payments Data

Vivian Tran, MD

Internal Medicine · San Diego, CANPI 1427492891

Payments from drug & device makers

$1,155in general payments, 2019–2025

Across 28 payments — averaging $41.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$141
  • Merck$135
  • Amgen$121
  • Teva Pharmaceuticals USA, Inc.$112
  • Galderma Laboratories, L.p.$104
  • Novo Nordisk$104
  • plus $437 from 8 others

What the payments were for

  • Food & beverage$1,155100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,155 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$68,722
Medicare patients
221
Services billed
1,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide14$33,950
EliquisApixaban25$28,117
JardianceEmpagliflozin13$15,672
Incruse ElliptaUmeclidinium Bromide11$5,656
SymbicortBudesonide/Formoterol Fumarate11$2,824
Rosuvastatin Calcium170$2,161
Levothyroxine Sodium118$1,803
Losartan Potassium158$1,539
Bupropion XlBupropion Hcl48$1,394
Atorvastatin Calcium152$1,322
Gabapentin48$1,311
Duloxetine Hcl23$1,088
ValacyclovirValacyclovir Hcl20$844
Lisinopril98$819
Metoprolol Succinate47$812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$104$33,95014 claims
PfizerEliquis$101$28,11725 claims
AstraZenecaSymbicort$141$2,82411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →